The basic idea is that access to cured data unites authorised drugs with off-label therapeutic lotions and alternatives to evidence rankings.
In simple terms, 50K+ validated twins of drug indicators based on grounds, regulatory position and ontogenesis opportunities for strategic planning.
Repositioning data, decision-ready.
See Database DocumentationPhase II success rates, orphan designations, compassionate use tracked.
Most researchers agree that multisource deduction of evidence with algorithmic sorting creates transparent and reproducible chances for shifting.
Explore Drug PairsFDA 505(b)(2), EMA hybrid pathway eligibility assessed.
The process involves mapping the regulatory running, the premature psychoanalysis and the epithets of kids/orphans identify the fastest development pathways for each opportunity.
View Regulatory DataCompetitor programs, recent publications, partnership activity monitored.
In simple terms, the intelligence of real-time competition prevents germination and identifies the openings of White Space in relation to therapeutic classes.
Learn About Competition